Understanding Cystoscopy and Surveillance: Your Long-Term NMIBC Plan

Non-Muscle Invasive Bladder Cancer (NMIBC) represents a significant portion of all bladder cancer diagnoses, accounting for approximately 75% of newly identified cases.1 This category includes tumors that are confined to the lining of the bladder and have not invaded the muscle layer. According to the American Joint Committee on Cancer (AJCC) staging system, NMIBC encompasses papillary tumors limited to the epithelial mucosa (stage Ta), tumors invading the subepithelial tissue (lamina propria; T1), and carcinoma in situ (Tis), which are flat, high-grade tumors also confined to the mucosa.1 While the initial survival prognosis for patients with NMIBC is generally favorable, particularly for low-grade disease, the condition is characterized by a high propensity for recurrence, with rates reaching up to 70%.5 Furthermore, a notable percentage of patients, ranging from 10% to 30% overall and higher in those with high-risk disease, may experience progression to muscle-invasive bladder cancer (MIBC), a more advanced stage associated with a poorer outcome.5 Given these substantial risks, long-term surveillance is not merely advisable but an absolute necessity in the management of NMIBC. This ongoing monitoring is critical for the early detection of both recurrent tumors and any progression to a more aggressive form of the disease, ultimately aiming to improve patient outcomes and maintain quality of life.

The approach to NMIBC surveillance is not uniform but rather tailored to an individual's risk of recurrence and progression. This risk-stratified strategy ensures that patients with a higher likelihood of adverse outcomes receive more intensive monitoring, while those at lower risk may undergo less frequent checks.2 Two of the most influential organizations providing guidelines for the management of NMIBC are the American Urological Association (AUA) and the European Association of Urology (EAU). The AUA, in collaboration with the Society of Urologic Oncology (SUO), issued an updated guideline amendment in 2023, incorporating new literature published between July 2019 and May 2023 into their existing recommendations.1 Their risk stratification system considers several factors, including tumor size, the number of tumors (focality), the grade of the tumor (low or high), and the stage (Ta, Tis, or T1).8 Based on this assessment, the AUA recommends specific surveillance schedules. For low-risk patients whose initial surveillance cystoscopy is negative, subsequent cystoscopies are advised at 6 to 9 months, then annually. Surveillance beyond five years without recurrence is guided by shared decision-making between the patient and clinician. Routine upper tract imaging is not typically recommended for asymptomatic patients with a history of low-risk NMIBC. Intermediate-risk patients with a negative first surveillance cystoscopy should undergo cystoscopy with urine cytology every 3 to 6 months for two years, then every 6 to 12 months for the subsequent two years, and annually thereafter. Surveillance upper tract imaging may be considered at one- to two-year intervals. High-risk patients with an initial negative surveillance cystoscopy require more frequent monitoring, with cystoscopy and cytology every 3 to 4 months for two years, then every 6 months for years three and four, and annually subsequently. Similar to intermediate-risk patients, surveillance upper tract imaging at one- to two-year intervals is also recommended.8

The European Association of Urology (EAU) also provides comprehensive guidelines for NMIBC, with the latest updates published in 2024 and further revisions in 2025.9 The EAU employs a risk stratification that categorizes patients into low, intermediate, high, and very high-risk groups.2 It is important to note that the definition of intermediate risk can differ between the EAU and other groups like the International Bladder Cancer Group (IBCG).7 According to the EAU guidelines, low-risk NMIBC patients should have a cystoscopy at 3 and 12 months, followed by annual cystoscopies for five years. Urine cytology and routine imaging are not recommended for this group. For intermediate-risk patients (excluding those with high-grade/G3 tumors, who are managed as high-risk), cystoscopy is advised at 3 months, then every 6 months for two years, and annually for up to ten years. Again, cytology and routine imaging are not recommended. High- and very high-risk patients require the most intensive surveillance, with cystoscopy and urine cytology every 3 months for the first two years, then every 6 months up to five years, and annually lifelong. Annual CT urography is recommended for up to five years, followed by every two years up to ten years, emphasizing regular and long-term upper tract imaging.16 The EAU guidelines highlight the significance of the first cystoscopy performed three months after the initial tumor resection (TURB) as an important prognostic indicator for both recurrence and progression.16

Risk Category	AUA Guidelines	EAU Guidelines
Low Risk	Cystoscopy at 3-4 months, then 6-9 months, then annually for 5 years.	Cystoscopy at 3 and 12 months, then annually for 5 years.
	Urine cytology not routine.	Urine cytology not recommended.
	Upper tract imaging not routine.	Imaging not systematic.
Intermediate Risk	Cystoscopy & cytology every 3-6 months for 2 years, then 6-12 months for 2 years, then annually.	Cystoscopy at 3 months, then every 6 months for 2 years, then annually for up to 10 years.
	Upper tract imaging consider every 1-2 years.	Urine cytology not recommended (except HG/G3 subgroup as high risk).
		Imaging not systematic.
High Risk	Cystoscopy & cytology every 3-4 months for 2 years, then every 6 months for 2 years, then annually.	Cystoscopy & cytology every 3 months for 2 years, then every 6 months up to 5 years, then annually lifelong.
	Upper tract imaging consider every 1-2 years.	CT urography annually up to 5 years, then every 2 years up to 10 years.

Cystoscopy stands as the cornerstone of NMIBC surveillance, serving as the primary modality for detecting bladder cancer recurrence.5 This procedure allows the urologist to directly visualize the lining of the bladder and the urethra, enabling the identification of any new or recurring tumors.5 Cystoscopy can be performed using either a flexible cystoscope, typically in an outpatient setting with local anesthesia, or a rigid cystoscope, often requiring general anesthesia in the operating room.20 The flexible approach is commonly used for routine surveillance, while rigid cystoscopy is often preferred when tissue biopsies or the removal of small tumors is necessary. Beyond simply visualizing the bladder, cystoscopy is crucial for detecting both papillary tumors, which are raised and often easily visible, and flat lesions such as Carcinoma in Situ (CIS), a more aggressive form of NMIBC that can be challenging to detect with other methods.5 In fact, studies indicate that standard white light cystoscopy may miss up to one-fourth of small malignant areas.5 Furthermore, cystoscopy plays an integral role in the initial management of NMIBC by facilitating transurethral resection of bladder tumors (TURBT), which is essential for diagnosis, staging, and the primary treatment of the disease.8 Advancements in cystoscopic techniques have further enhanced its utility. Blue light cystoscopy (BLC), for instance, utilizes a photosensitizing agent instilled into the bladder that causes malignant lesions to fluoresce under blue light, thereby improving their detection and potentially reducing recurrence rates.1 Research has shown that BLC can detect a significant percentage of tumors that would be missed by standard white light cystoscopy.25 While white light cystoscopy remains the standard, its limitations in detecting subtle lesions underscore the value of adjunct methods like blue light cystoscopy when available and appropriate for the patient's risk profile.10

Failure to adhere to the recommended surveillance schedule can have significant negative consequences for individuals with NMIBC. The risk of recurrence is substantial, with studies showing that 50% to 70% of patients will experience a recurrence 24, and this can be as high as 78% within five years depending on various risk factors.6 Without regular follow-up, these recurrences may go undetected until they reach a more advanced stage or progress to muscle-invasive bladder cancer (MIBC), which occurs in 10% to 30% of patients overall, with a higher risk in those with high-risk NMIBC.6 MIBC carries a much poorer prognosis and requires more aggressive treatment strategies.7 Even in cases of low-risk NMIBC, where the likelihood of progression is lower, the risk of recurrence remains significant, with approximately 50% of patients experiencing a recurrence within four years.28 Notably, late recurrences can occur even after a patient has been recurrence-free for five years.15 Studies have documented varying recurrence rates based on the initial tumor characteristics, with low-grade Ta tumors having a 5-10% recurrence risk, high-grade Ta tumors a 15-40% risk, and T1 high-grade tumors a 30-50% risk.7 Furthermore, lifestyle factors such as smoking have been shown to increase the risk of both recurrence and progression in NMIBC patients.29 Therefore, consistent and timely surveillance is paramount for early detection and intervention, which can significantly impact the long-term management and outcomes of NMIBC.

Regular surveillance plays a crucial role in improving patient outcomes for NMIBC. By enabling the early detection of recurrent tumors, surveillance often allows for treatment at an earlier stage, which can be less invasive and associated with better outcomes.6 For instance, small recurrences detected early may be amenable to office-based management rather than requiring more extensive surgical intervention in the operating room. Emerging evidence suggests that the use of blue light cystoscopy during surveillance may further enhance outcomes by reducing the risk of recurrence compared to traditional white light cystoscopy.4 One study demonstrated that BLC significantly delayed the time to recurrence, highlighting the potential benefit of this enhanced imaging technique.24 While research continues to refine the optimal intensity of surveillance, current guidelines from expert organizations represent a consensus aimed at maximizing early detection based on the best available evidence.30 It is important to acknowledge that the frequent cystoscopies and other surveillance procedures can impact a patient's quality of life.26 This underscores the need for a balanced approach that ensures effective monitoring while also considering the patient's well-being and preferences. Ongoing research into less invasive surveillance methods, such as the use of circulating tumor DNA (ctDNA) analysis, shows promise as a potential tool for early detection of relapse and progression, even when standard surveillance findings are normal.34 Such advancements may offer opportunities to personalize surveillance strategies further and potentially reduce the burden of frequent cystoscopies in the future.

Cystoscopy is a direct visual examination that allows the urologist to identify any signs of bladder cancer recurrence or progression. During the procedure, the entire lining of the bladder is carefully inspected for any abnormalities.8 This includes looking for new tumor growths, changes in previously treated areas, or any suspicious-looking patches or lesions. Different types of bladder cancer can have distinct appearances under cystoscopy. For example, papillary tumors typically appear as raised, finger-like projections, while Carcinoma in Situ (CIS) may present as a flat, velvety area that can be easily overlooked with standard white light.5 If any suspicious areas are identified during the cystoscopy, particularly during a rigid cystoscopy, the urologist can take biopsies – small tissue samples – and send them to a pathology lab for microscopic examination. This is crucial for confirming whether the abnormality is indeed cancerous and, if so, determining its grade and stage.17 Enhanced cystoscopy techniques like blue light cystoscopy improve the ability to detect subtle lesions, especially CIS, by causing them to fluoresce brightly under blue light, making them more visible compared to white light.10 While cystoscopy is a highly effective tool, it is important to recognize that it may not detect every single recurrence, particularly very small or microscopic disease.20 Studies have shown that the sensitivity of cystoscopy in detecting bladder tumors is around 81%.35 This highlights the importance of using cystoscopy in conjunction with other surveillance methods and for patients to remain vigilant about any new symptoms that may arise.

In addition to cystoscopy, urine cytology and various urinary biomarker tests play complementary roles in the surveillance of NMIBC. Urine cytology involves the microscopic examination of a urine sample to identify any abnormal or cancerous cells that may have been shed from the lining of the urinary tract.8 This non-invasive test is particularly useful for detecting high-grade tumors and CIS, as these types of cancer tend to shed more cells into the urine.36 While urine cytology has a high specificity, meaning a positive result is often accurate, its sensitivity, especially for low-grade tumors, can be variable and often lower.19 This means that while a positive cytology result may strongly suggest the presence of high-grade disease, a negative result does not necessarily rule out the possibility of a low-grade recurrence. A variety of urinary biomarker tests have been developed to aid in NMIBC surveillance.1 These tests analyze different substances in the urine, such as proteins, DNA, or RNA, that may be indicative of cancer. Examples include NMP22, BTA stat, ImmunoCyt, UroVysion, Uromonitor, Cxbladder, XPERT BC Monitor, and EpiCheck. These biomarkers offer the potential for non-invasive detection of recurrence and in some cases, may have better sensitivity for certain tumor grades compared to cytology. However, it is important to note that some guidelines, such as those from NICE, do not routinely recommend the use of urinary biomarkers or cytology for the follow-up of low-risk bladder cancer.11 Furthermore, the AUA guidelines explicitly state that urinary biomarkers should not be used as a replacement for cystoscopic evaluation in surveillance.8 In contrast, the EAU guidelines acknowledge the potential of certain high-performing biomarkers like Bladder EpiCheck to potentially replace or postpone cystoscopies in low- and intermediate-risk NMIBC patients due to their high sensitivity and negative predictive value for high-grade disease.1 Despite the promise of urinary markers, it is generally agreed that no current biomarker can completely replace cystoscopy due to limitations in diagnostic accuracy and the potential for false positive results.19 Therefore, cystoscopy remains the central component of NMIBC surveillance, with urine cytology and biomarker tests serving as valuable adjuncts in specific clinical scenarios.

In conclusion, regular follow-up, with cystoscopy serving as the cornerstone, is of paramount importance for the long-term management of Non-Muscle Invasive Bladder Cancer. The high risks of both recurrence and progression necessitate vigilant monitoring to ensure early detection and timely intervention. The benefits of regular cystoscopy include the direct visualization of the bladder lining, enabling the identification of new or recurrent tumors and facilitating biopsies for accurate diagnosis. Adherence to risk-stratified surveillance guidelines, such as those provided by the American Urological Association and the European Association of Urology, is crucial for optimizing patient outcomes. While advancements in enhanced cystoscopy techniques like blue light cystoscopy are improving detection rates, and promising urinary biomarkers continue to be developed, cystoscopy remains the gold standard for NMIBC surveillance. The evolving landscape of NMIBC management suggests a future where personalized surveillance plans, potentially incorporating novel biomarkers, may further enhance early detection and reduce the burden of frequent invasive procedures. Ultimately, effective long-term management requires ongoing communication and collaboration between patients and their urologists to establish and maintain a surveillance plan that balances the need for rigorous monitoring with the individual's quality of life and preferences.

Works cited

1. www.auajournals.org, accessed May 1, 2025, https://www.auajournals.org/doi/pdf/10.1097/JU.0000000000003846

2. AUA 2023: The Role of Flexible Blue Light Cystoscopy in ..., accessed May 1, 2025, https://www.urotoday.com/conference-highlights/aua-2023/aua-2023-bladder-cancer/143973-aua-2023-mp08-15-the-role-of-flexible-blue-light-cystoscopy-in-surveillance-of-non-muscle-invasive-bladder-cancer-results-from-a-nordic-registry.html

3. Intermediate and high-risk non-muscle-invasive bladder cancer: an overview of epidemiology, burden, and unmet needs - PubMed Central, accessed May 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10272547/

4. Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment | Journal of Urology, accessed May 1, 2025, https://www.auajournals.org/doi/10.1097/JU.0000000000003846

5. Bladder Cancer: Practice Essentials, Background, Anatomy, accessed May 1, 2025, https://emedicine.medscape.com/article/458825-overview

6. Bladder Cancer Recurrence: The Importance of Surveillance, accessed May 1, 2025, https://www.cxbladder.com/row/blog/the-importance-of-monitoring-and-surveillance/

7. AUA 2023: Intermediate Risk NMIBC: Surveillance and Treatment Challenges - UroToday, accessed May 1, 2025, https://www.urotoday.com/conference-highlights/aua-2023/aua-2023-bladder-cancer/144082-aua-2023-intermediate-risk-nmibc-surveillance-and-treatment-challenges.html

8. Bladder Cancer: Non-Muscle Invasive Guideline - American ..., accessed May 1, 2025, https://www.auanet.org/guidelines-and-quality/guidelines/bladder-cancer-non-muscle-invasive-guideline

9. EAU Guidelines on Non-muscle-invasive Bladder Cancer - Uroweb, accessed May 1, 2025, https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer

10. The use of blue-light cystoscopy in the detection and surveillance of nonmuscle invasive bladder cancer - PMC, accessed May 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC9527925/

11. Comparison of Guidelines on Non-Muscle Invasive Bladder Cancer ..., accessed May 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4927900/

12. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ)-A Summary of the 2024 Guidelines Update - PubMed, accessed May 1, 2025, https://pubmed.ncbi.nlm.nih.gov/39155194/

13. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ) - PubMed, accessed May 1, 2025, https://pubmed.ncbi.nlm.nih.gov/34511303/

14. European Association of Urology Guidelines on Non–muscle- invasive Bladder Cancer (Ta, T1, and Carcinoma in Situ) - cloudfront.net, accessed May 1, 2025, https://d56bochluxqnz.cloudfront.net/documents/guideline-publications/non-muscle-invasive-bladder-cancer/Babjuk-M-et-al.-Eur-Urol-2022-81175.-European-Association-of-Urology-Guidelines-on-Non-muscle-invasive-Bladder-Cancer-Ta-T1-and-Carcinoma-in-Situ.pdf

15. Long-Term Recurrence Risk, Metastatic Potential, and Length of ..., accessed May 1, 2025, https://www.auajournals.org/doi/10.1097/JU.0000000000004305

16. EAU Guidelines on Non-muscle-invasive Bladder Cancer - Uroweb, accessed May 1, 2025, https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/followup-of-patients-with-nmibc

17. How Do Doctors Find Bladder Cancer?, accessed May 1, 2025, https://bcan.org/facing-bladder-cancer/bladder-cancer-diagnosing-and-monitoring/

18. Urinary Tumor Markers for Bladder Cancer, accessed May 1, 2025, https://www.myrxtoolkit.com/web/public/brands/medicalpolicy/external-policies/urinary-tumor-markers-for-bladder-cancer/

19. Clinical Decision Making in Surveillance of Non–Muscle-Invasive Bladder Cancer: The Evolving Roles of Urinary Cytology and Molecular Markers, accessed May 1, 2025, https://www.cancernetwork.com/view/clinical-decision-making-surveillance-nonmuscle-invasive-bladder-cancer-evolving-roles-urinary

20. Detecting Bladder Cancer with a Cystoscopy | Cxbladder, accessed May 1, 2025, https://www.cxbladder.com/row/bladder-cancer/detection/cystoscopy/

21. Bladder cancer - Diagnosis and treatment - Mayo Clinic, accessed May 1, 2025, https://www.mayoclinic.org/diseases-conditions/bladder-cancer/diagnosis-treatment/drc-20356109

22. Cystoscopy in Bladder Carcinoma Overview of Cystoscopy - Medscape Reference, accessed May 1, 2025, https://emedicine.medscape.com/article/1950345-overview

23. MP08-15 THE ROLE OF FLEXIBLE BLUE LIGHT CYSTOSCOPY IN SURVEILLANCE OF NON-MUSCLE INVASIVE BLADDER CANCER. RESULTS FROM A NORDIC REGISTRY | Journal of Urology, accessed May 1, 2025, https://www.auajournals.org/doi/10.1097/JU.0000000000003223.15

24. Implementing Blue Light Flexible Cystoscopy in Non-Muscle Invasive Bladder Cancer Surveillance - European Medical Journal - EMJ, accessed May 1, 2025, https://www.emjreviews.com/urology/article/implementing-blue-light-flexible-cystoscopy-in-non-muscle-invasive-bladder-cancer-surveillance/

25. UVA Uses Enhanced Cystoscopy to Minimize Bladder Cancer Recurrence, accessed May 1, 2025, https://www.uvaphysicianresource.com/enhanced-cystoscopy-minimize-bladder-cancer-recurrence/

26. Quality of life in patients undergoing surveillance for non-muscle invasive bladder cancer—a systematic review, accessed May 1, 2025, https://tau.amegroups.org/article/view/64984/html

27. Quality of life in patients undergoing surveillance for non-muscle invasive bladder cancer—a systematic review - ResearchGate, accessed May 1, 2025, https://www.researchgate.net/publication/352448901_Quality_of_life_in_patients_undergoing_surveillance_for_non-muscle_invasive_bladder_cancer-a_systematic_review

28. Long-term Recurrence Rates of Low-risk Non-muscle-invasive Bladder Cancer-How Long Is Cystoscopic Surveillance Necessary? - PubMed, accessed May 1, 2025, https://pubmed.ncbi.nlm.nih.gov/37442722/

29. Non-muscle-invasive Bladder Cancer - DISEASE MANAGEMENT - Uroweb, accessed May 1, 2025, https://uroweb.org/guidelines/non-muscle-invasive-bladder-cancer/chapter/disease-management

30. The impact of low- versus high-intensity surveillance cystoscopy on surgical care and cancer outcomes in patients with high-risk non-muscle-invasive bladder cancer (NMIBC) | PLOS One, accessed May 1, 2025, https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0230417

31. Is low-intensity surveillance feasible for patients with high-risk NMIBC? - Urology Times, accessed May 1, 2025, https://www.urologytimes.com/view/is-low-intensity-surveillance-feasible-for-patients-with-high-risk-nmibc

32. Bladder EpiCheck® Included in 2022 European Association of Urology (EAU) Clinical Guidelines on Non-Muscle Invasive Bladder Cancer (NMIBC) | Business Wire, accessed May 1, 2025, https://www.businesswire.com/news/home/20220316005302/en/Bladder-EpiCheck%C2%AE-Included-in-2022-European-Association-of-Urology-EAU-Clinical-Guidelines-on-Non-Muscle-Invasive-Bladder-Cancer-NMIBC

33. Quality of life in patients undergoing surveillance for non-muscle ..., accessed May 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8261437/

34. Surveillance with plasma ctDNA in non-muscle invasive bladder ..., accessed May 1, 2025, https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.864

35. Cystoscopy Accuracy in Detecting Bladder Tumors: A Prospective Video-Confirmed Study, accessed May 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10777997/

36. Unleashing the power of urine‑based biomarkers in diagnosis, prognosis and monitoring of bladder cancer (Review) - Spandidos Publications, accessed May 1, 2025, https://www.spandidos-publications.com/10.3892/ijo.2025.5724

37. Review of non-invasive urinary biomarkers in bladder cancer - PMC, accessed May 1, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8798424/

38. Uromonitor: Clinical Validation and Performance Assessment of a ..., accessed May 1, 2025, https://www.auajournals.org/doi/10.1097/JU.0000000000004335